Navigation Links
Cadus Reports Second Quarter 2008 Results
Date:8/14/2008

NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Cadus Corporation (OTC Bulletin Board: KDUS) announced today financial results for the second quarter ended June 30, 2008.

Revenues were $0 for the second quarter of 2008 and for the same period in 2007. Net income for the second quarter of 2008 was $52,795, compared to net income of $218,960 for the same period in 2007. Basic net income per share for the second quarter of 2008 was $0.00, compared to basic net income per share for the second quarter of 2007 of $0.02.

Revenues were $100,000 for the first six months of 2008 and for the same period in 2007. Net loss for the first six months of 2008 was $155,201, compared to a net loss of $339,509 for the same period in 2007. Basic net loss per share for the first six months of 2008 was $0.01, compared to a basic net loss per share for the same period in 2007 of $0.03.

As of June 30, 2008, Cadus had 13,144,040 shares outstanding.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2007. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of patent protection and the risk of obsolescence of the company's technologies.

CADUS CORPORATION

Condensed Consolidated Balance Sheets

ASSETS

June 30, December 31,

2008 2007

(Un
'/>"/>

SOURCE Cadus Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cadus Reports First Quarter 2008 Results
2. Cadus Reports Second Quarter 2007 Results
3. Cadus Reports Third Quarter 2007 Results
4. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
5. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
6. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
7. Derma Sciences Reports Second Quarter 2008 Results
8. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
9. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
10. NeurogesX Reports Second Quarter 2008 Results
11. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... 27 Following the successful acquisition of,Drug Development ... organization, announced today that it has fully,integrated its ... branded as,Chiltern Early Phase., Chiltern Early Phase ... pharmaceutical industry via its two well established units ...
... 26 Based on its recent analysis,of the ... presents Kionix, Inc. with the 2008 Global Frost ... a leadership position,in analog output accelerometer products, and ... KXSC7 accelerometer release, a natural extension of,its product ...
... Industries is,pleased to announce the addition of long ... newest member on their Board of Directors., ... Mr.,Skiven oversaw during his 15 years as Executive ... logical that he would join the board of ...
Cached Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 3Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 4GM Exec Joins Bio-Reaction Industries' Board of Directors 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A 23andMe study of consumers, reactions to genetic testing ... in individuals, those individuals had few negative reactions to ... results prompted people to take positive steps, including follow-up ... who could also be at risk. The study, ...
... researchers "cured" a strain of bacteria of its ability ... implications for a long-standing public health crisis. ... to remove the ability of the Pseudomonas aeruginosa microorganism ... access to food and oxygen. Over 120 ...
... researcher has identified characteristics in benign breast disease ... Michele Cote, Ph.D., associate professor of oncology ... Ann Karmanos Cancer Institute, recently reviewed data from ... underwent breast biopsies between 1997 and 2000. Researchers ...
Cached Biology News:Consumers have few negative reactions to the results of genetic testing for cancer mutations 2Lack of energy an enemy to antibiotic-resistant microbes 2Lack of energy an enemy to antibiotic-resistant microbes 3Cancer risk for African-American women with benign breast disease factors Wayne State finds 2
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Biology Products: